Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-209670 SCHEMBL29550762 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Sb-209670 SCHEMBL4197810 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Sb-209670 SCHEMBL8734573 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Sb-209670 SCHEMBL6953911 | 0.99 | EDNRA (0.98) | EDNRAEDNRB | |
| Sb-209670 SCHEMBL7532946 | 0.99 | EDNRA (0.98) | EDNRAEDNRB | |
| Sb-209670 SCHEMBL6953904 | 0.99 | EDNRA (0.98) | EDNRAEDNRB | |
| Sb-209670 SCHEMBL7664400 | 0.99 | EDNRA (0.98) | EDNRAEDNRB | |
| SCHEMBL8204582 | 0.97 | EDNRA (0.94) | EDNRAEDNRB | |
| SCHEMBL8203979 | 0.95 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL13038489 | 0.95 | EDNRA (0.93) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | claimed |
| US-5817693-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1998-10-06 | — | — | US | claimed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2246062-B1 | Methods and compositions for emergency contraception using endothelin receptor antagonists | POPULATION COUNCIL INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8173593-B2 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | GULATI ANIL (US) | 2012-03-22 | — | — | US | disclosed |
| US-7976835-B2 | Methods and compositions for preventing and treating solid tumors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-07-12 | — | — | US | disclosed |
| EP-1906987-B1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | POPULATION COUNCIL INC (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-0876352-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5817693-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1998-10-06 | — | — | US | disclosed |
| US-5719183-A | HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5719182-A | TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1997017071-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017330-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| EP-0699069-A4 | — | — | 1996-04-03 | — | — | EP | disclosed |
| EP-0699069-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994025013-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885 |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | EDNRB, EGLN3, BDKRB2 | EDNRA 4/4885EDNRB 1/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885 |
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.